Santiago Ponce-Aix

TL;DR: The RELAY trial as mentioned in this paper evaluated erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC.

TL;DR: The peptide nucleic acid-mediated 5´ nuclease real-time polymerase chain reaction (TaqMan) assay used in this study can be used to efficiently assess EGFR mutations in cfDNA and may be a novel surrogate prognostic marker.

TL;DR: PD-L1 is expressed in 20% of patients, associated with no epithelioid histology and poor prognostic in MPM, and these results suggest PD-L 1 warrants further exploration in selecting p for immunotherapy.

TL;DR: The IMPULSE study showed no relevant effect of lefitolimod on the main efficacy end point OS in the ITT, but the expected pharmacodynamic response to lefitolinimod, positive OS efficacy signals in two predefined subgroups and a favorable safety profile support further exploration of le FitolIMod in SCLC.

TL;DR: Digital NGS of ctDNA in lung cancers with insufficient tumor samples for tissue sequencing detects actionable variants that frequently co-occur with other potentially clinically relevant genomic alterations, allowing timely initiation of genotype-matched therapies.